Claims

1. Cyclo(-Tyr-His-X-Cys-Ser-Ala-^{D}Pro-Dab-Arg-Tyr-Cys-Tyr-~~Arg~~-Gln-Lys-^{D}Pro-Pro), disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof, with X being Ala or Tyr.

2. Compounds according to claim 1 for use as therapeutically active substances.

3. Compounds according to claim 1 having CXCR4 antagonizing activity and being useful for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immuno suppression; or for treating inflammation, or for stem cell mobilisation of peripheral blood stem cells and/or mesenchymal stem cell (MSC) and/or other stem cells which retention depend on the CXCR4-receptor.

4. A pharmaceutical composition containing a compound according to claim 1 and a pharmaceutically inert carrier.

5. Compositions according to claim 4 in a form suitable for oral, topical, transdermal, injection, buccal, transmucosal, pulmonary or inhalation administration.

6. Compositions according to claim 4 or 5 in form of tablets, dragees, capsules, solutions, liquids, gels, plaster, creams, ointments, syrup, slurries, suspensions, spray, nebuliser or suppositories.

7. The use of compounds according to claim 1 for the manufacture of a CXCR4 antagonizing medicament.

8. The use according to claim 7 wherein said CXCR4 antagonizing medicament is intended to be used for preventing HIV infections in healthy individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting fromCXCR4 receptor activity; or where immunological diseases are mediated